AbbVie hikes full-year earnings guidance as Humira sales top estimates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- Nasdaq set to fall at open as DeepSeek's AI chip push rattles markets
- Oil gains after vessels attacked near Strait of Hormuz
- Citi says SpaceX stock has path to $900+ valuation. Here’s how
- Tesla stock target lifted at RBC on potential SpaceX merger
- Short squeezes more likely than widespread selling: Citi
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Coursera plans layoffs after Udemy merger, estimates $8M-$11M in costs
AbbVie Reports Second-Quarter 2024 Financial Results
July 25, 2024 7:36 AM EDTReports Second-Quarter Diluted EPS of $0.77 on a GAAP Basis, a Decrease of 32.5 Percent; Adjusted Diluted EPS of $2.65, a Decrease of 8.9 Percent; These Results Include an Unfavorable Impact of $0.52 Per Share Related to Acquired IPR&D and Milestones ExpenseÂ
 Delivers Second-Quarter Net Revenues of $14.462 Billion, an Increase of 4.3 Percent on a Reported Basis and 5.6 Percent on an Operational BasisÂ
 Second-Quarter Global Net Revenues from the Immunology Portfolio Were $6.971 Billion, an Increase of 2.3 Percent on a Reported Basis, or 3.5 Percent on... More
